<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035437</url>
  </required_header>
  <id_info>
    <org_study_id>RPCI I 148809</org_study_id>
    <nct_id>NCT01035437</nct_id>
  </id_info>
  <brief_title>Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer</brief_title>
  <official_title>A Pilot Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim is to find out what effects capecitabine, oxaliplatin and radiation therapy
      following photodynamic therapy have on esophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no accrual
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the toxicity of sequential PDT and chemoradiation in obstructing esophageal cancer</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of PDT in palliation of dysphagia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Esophageal Neoplasm</condition>
  <arm_group>
    <arm_group_label>HPPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPPH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)</intervention_name>
    <description>HPPH in D5W, 4.0 mg/m2 infused over 1 hour</description>
    <arm_group_label>HPPH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Partially or completely obstructing primary esophageal carcinoma, clinical stage I-IVa
             as determined by endoscopy, CT-scan, PET +/- endoscopic ultrasound. For distal
             esophagus tumors involving the GE junction, at least 50% or greater of the tumor bulk
             should be in the distal esophagus

          -  Ineligible for or refused surgical resection

          -  No Prior therapy allowed for esophageal cancer

          -  ECOG Performance status 0-1

          -  Life expectancy &gt; 4 months

          -  Adequate hematologic parameters (hemoglobin&gt; 9g/dl, ANC &gt; 1500/ul, Platelets &gt;
             100,000/ul)

          -  Adequate biochemical parameters (total bilirubin and creatinine within institutional
             limits, AST and alkaline phosphatase less tham or equal to 3xUNL)

          -  Age &gt; 18 years

          -  Signed informed consent

          -  Bronchoscopy with biopsy and cytology if primary esophageal cancer is &lt; 26 cm from
             incisors

          -  Female patients of childbearing potential should have a negative serum or urine
             pregnancy test within 7 days prior to registration

          -  Patients of Childbearing potential agree to use an effective form of contraception
             during the study and for 90 days following the last dose of study medication (an
             effective form of contraception is an oral contraceptive or a double barrier method

          -  Both men and women and members of all races and ethnic are eligible for this trial

        Exclusion Criteria:

          -  Hypersensitivity to platinum compounds, fluoropyrimidines or to antiemetics
             appropriate for administration in conjunction with protocol-directed chemotherapy

          -  Patients may not be receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this trail

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Peripheral neuropathy â‰¥ Grade 2

          -  History of second malignancy within the previous years except for curatively treated
             carcinoma of the cervix in-situ or non-melanomatous skin cancer

          -  Patients who are pregnant or lactating

          -  Porphyria or hypersensitivity to porphyrin-like compounds

          -  Patients with known HIV or Hepatitis B or C (active, previously treated or both)

          -  Patients with tracheal or bronchial involvement, as determined by bronchoscopy

          -  Patients with documented unilateral or bilateral vocal cord paralysis

          -  Patients with T4 lesions by CT, MRI or EUS involving the aorta, lung or pericardium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil Khushalani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>June 28, 2012</last_update_submitted>
  <last_update_submitted_qc>June 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obstructing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

